Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure: A Randomized, Double-blind, Placebo Controlled Trial

NCT04208581 Phase 3 UNKNOWN

This study aims to establish the treatment scheme of Yiqi Huoxue Huatan granule for chronic obstructive pulmonary disease (COPD) with chronic respiratory failure (CRF), reducing mortality, improving quality of life and forming high quality evidence.

Details

Lead sponsor	Peking University People's Hospital
Phase	Phase 3
Status	UNKNOWN
Enrolment	372
Start date	2019-10-08
Completion	2021-12

Conditions

• Chronic Obstructive Pulmonary Disease
• Chronic Respiratory Failure

Interventions

• Yiqi Huoxue Huatan granule
• Placebo Yiqi Huoxue Huatan granule

Primary outcomes

• All-cause mortality — Up to week 52 of the follow-up phase.
  All-cause mortality will be calculated in this study.
• Frequency of acute exacerbation of COPD — Up to week 52 of the follow-up phase.
  Frequency of acute exacerbation of COPD will be recorded.

Countries

China